Founded in 2002, Tang Capital Management is a San Diego-based venture capital investment firm specializing in life sciences.
Kevin C. Tang, the founder and President of Tang Capital Management LLC, has an extensive background in the life sciences sector. He founded Ardea Biosciences, Inc. in 1994 and holds positions as Chief Executive Officer & Director at Jounce Therapeutics, Inc., Chairman & Chief Executive Officer at Odonate, Inc., and Chief Executive Officer at Concentra Biosciences LLC. Additionally, he serves as a Director at Tetraphase Pharmaceuticals, Inc. Previously, Mr. Tang chaired Heron Therapeutics, Inc. from 2012 to 2020 and La Jolla Pharmaceutical Co. from 2014 to 2022. He has held director roles at Trimeris, Inc., Penwest Pharmaceuticals Co., ACLARA Biosciences, Inc., IntraBiotics Pharmaceuticals, Inc., RadPharm, Inc., Prospect Therapeutics, Inc., and managed the Life Sciences Research Group at Deutsche Bank Securities, Inc. Mr. Tang earned his undergraduate degree from Duke University in 1989.
Tang Capital Management reported $960,446,074 in managed 13F securities in their Q1 2024 filing, with a top 10 holdings concentration of 38.43%. Their largest holding is Tarsus Pharmaceuticals, Inc., with 2,254,797 shares held.
| Fund Name: | Tang Capital Management |
| Manager | Kevin C. Tang |
| Portfolio Value | $1,399,857,815 |
| Change This QTR | +1.43% |
| No. | Security | Ticker | Shares | Value | Activity | % Port | History |
|---|---|---|---|---|---|---|---|
| 1. | EOLS | 4,847,399 | $78,527,864 | 5.6% | |||
| 2. | TARS | 2,254,797 | $74,160,273 | 5.29% | |||
| 3. | AUPH | 7,229,500 | $52,992,235 | +161% | 3.78% | ||
| 4. | Viridian Therapeutics Inc. | 2,242,925 | $51,026,544 | +62% | 3.64% | ||
| 5. | MIRM | 1,287,107 | $50,197,173 | 3.58% |
| Symbol | Company | Filed By | Filing Date | Filing |
|---|---|---|---|---|
| 2024-12-03 | ||||
| 2024-11-29 | ||||
| 2022-04-21 | ||||
| 2022-04-21 |
